Chromadex Corp (NASDAQ:CDXC)’s traded shares stood at 1.04 million during the last session, with the company’s beta value hitting 2.04. At the close of trading, the stock’s price was $6.82, to imply a decrease of -5.28% or -$0.38 in intraday trading. The CDXC share’s 52-week high remains $7.58, putting it -11.14% down since that peak but still an impressive 80.65% since price per share fell to its 52-week low of $1.32. The company has a valuation of $520.93M, with an average of 1.65 million shares in intraday trading volume over the past 10 days and average of 1.05 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Chromadex Corp (CDXC), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CDXC a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Chromadex Corp (NASDAQ:CDXC) trade information
After registering a -5.28% downside in the last session, Chromadex Corp (CDXC) has traded red over the past five days. The 5-day price performance for the stock is 4.92%, and 98.26% over 30 days. With these gigs, the year-to-date price performance is 376.92%. Short interest in Chromadex Corp (NASDAQ:CDXC) saw shorts transact 2.6 million shares and set a 9.98 days time to cover.
Chromadex Corp (CDXC) estimates and forecasts
Looking at statistics comparing Chromadex Corp share performance against respective industry, we note that the company has outperformed competitors. Chromadex Corp (CDXC) shares are 106.67% up over the last 6 months, with its year-to-date growth rate higher than industry average at 157.14% against 17.70%. The rating firms project that company’s revenue will grow 16.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 26.52M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 27.74M.Earnings reports from the last fiscal year show that sales brought in 21.2M and 22.15M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 25.09% before jumping 25.23% in the following quarter.
CDXC Dividends
Chromadex Corp has its next earnings report out on 2025-Mar-04. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Chromadex Corp (NASDAQ:CDXC)’s Major holders
Chromadex Corp insiders hold 35.39% of total outstanding shares, with institutional holders owning 23.76% of the shares at 36.78% float percentage. In total, 23.76% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 3.39 million shares (or 4.5014% of shares), all amounting to roughly $9.24 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 3.12 million shares, or about 4.1422% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $8.51 million.
